Formulated for hypercholesterolemia to manage LDL levels and support cardiovascular risk reduction.
Mechanism of Action
Bempedoic acid inhibits adenosine triphosphate-citrate lyase (ACL), an enzyme upstream of HMG-CoA reductase in the cholesterol biosynthesis pathway. This action increases LDL receptor expression on hepatocytes, enhancing LDL clearance from the blood.
Route of Administration
Oral
Onset Time
2–4 weeks
Duration
15–24 hours (half-life)
Contraindications
Hypersensitivity to bempedoic acid, Pregnancy, Breastfeeding
Severe Adverse Events
Tendon rupture, Gout, Anaphylaxis — requires immediate medical attention
Common Side Effects
Muscle spasms, Back pain, Abdominal pain
Uncommon Side Effects
Hyperuricemia, Anemia, Elevated liver enzymes
Drug Interactions
Simvastatin, Pravastatin, Alcohol
Pregnancy Safety Warnings
FDA Category C: Use not recommended. Breastfeeding: Not recommended.
Age Restrictions
Safety and efficacy in pediatric patients have not been established.
Information related to Bempedoic Acid is compiled and periodically reviewed with reference to established medical sources and prescribing guidance. Content is provided for general reference and should be confirmed with a registered healthcare professional before use.
